We were quite interested in Ebrahimi et al.'s original manuscript.1 This study, which investigated whether there is a familial cluster of adverse liver-related outcomes, stands out for its comprehensive approach and the valuable insights provided. Researchers discovered a specific familial clustering of adverse liver-related outcomes in families of people with MASLD-associated fibrosis and identified at-risk populations, which could guide the development of preventative or therapeutic strategies.